Indian drugmaker Cipla has launched Spirofy, the country’s first pneumotach based portable, wireless Spirometer, on the eve of World COPD Day. With this launch, the company said it intends to bring a breakthrough change in  obstructive airway disease (OAD) diagnosis in line with its ambition to strengthen its position as the lung leader in India. This a part of the company’s ‘LungAttack’ campaign that endeavors to drive awareness about COPD and encourage early diagnosis.

The company said that Spirofy is a result of 5 years of meticulous in-house research by the integrated product development team, and it aims to transform OAD diagnosis in India. This advanced device ensures high result accuracy and individual patient safety using Bacterial Viral Filters. It is entirely wireless with robust battery backup, making it suitable for use in outdoor camps, remote areas with power shortages, or simply providing physicians’ flexibility and ease of use. The device generates reports in real-time, which can be printed using a portable wireless thermal printer instantly, or a pdf version can be shared on the phone. Cipla will undertake training of physicians in the interpretation of spirometry results.